Literature DB >> 16354745

Activity of mecillinam against ESBL producers in vitro.

K Thomas, M J Weinbren, M Warner, N Woodford, D Livermore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16354745     DOI： 10.1093/jac/dki451

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  14 in total

1.  Monomer complexes of polyadenylic acid.

Authors:  R Jeremy; H Davies
Journal:  Biochem Soc Trans       Date:  1975       Impact factor: 5.407

2.  In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.

Authors:  Shawn Vasoo; Scott A Cunningham; Nicolynn C Cole; Peggy C Kohner; Sanjay R Menon; Kevin M Krause; Kelly A Harris; Partha P De; Tse Hsien Koh; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

3.  In Vivo Evolution of CTX-M-215, a Novel Narrow-Spectrum β-Lactamase in an Escherichia coli Clinical Isolate Conferring Resistance to Mecillinam.

Authors:  Minggui Wang; Qinglan Guo; Mengyun Yin; Guoping Hu; Zhen Shen; Chengli Fang; Xuefei Zhang; Dan Li; Yohei Doi; Yu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

4.  Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.

Authors:  N T Mutters; S Zimmermann; M Kaase; A Mischnik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-10-03       Impact factor: 3.267

5.  Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Authors:  P R S Lagacé-Wiens; F Tailor; P Simner; M DeCorby; J A Karlowsky; A Walkty; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

6.  In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.

Authors:  M Tärnberg; A Ostholm-Balkhed; H-J Monstein; A Hällgren; H Hanberger; L E Nilsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-06       Impact factor: 3.267

7.  Activity of mecillinam against carbapenem-resistant Enterobacterales.

Authors:  Cécile Emeraud; Alexandre Godmer; Delphine Girlich; Océane Vanparis; Fériel Mahamdi; Elodie Creton; Agnès B Jousset; Thierry Naas; Rémy A Bonnin; Laurent Dortet
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

8.  Resistance to Mecillinam and Nine Other Antibiotics for Oral Use in Escherichia coli Isolated from Urine Specimens of Primary Care Patients in Germany, 2019/20.

Authors:  Michael Kresken; Yvonne Pfeifer; Florian Wagenlehner; Guido Werner; Esther Wohlfarth; On Behalf Of Study Group 'Antimicrobial Resistance' Of The Paul Ehrlich Society For Infection Therapy
Journal:  Antibiotics (Basel)       Date:  2022-05-31

9.  High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Silje Bakken Jørgensen; Knut Liestøl; Pål A Jenum
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

10.  Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.

Authors:  Fardod O'Kelly; Siobhan Kavanagh; Rustom Manecksha; John Thornhill; Jérôme P Fennell
Journal:  BMC Infect Dis       Date:  2016-11-03       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.